{
  "model": "gemini-2.5-pro",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gemini-2-5-pro-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 300382,
  "agentCostUsd": 0.10650500000000002,
  "graderCostUsd": 0.01795675,
  "totalCostUsd": 0.12446175000000001,
  "modelVersions": ["gemini-2.5-pro"],
  "agentFinalText": "- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": false,
      "groundingValid": false,
      "errors": [
        "datasets_or_cohorts.2.description: Too small: expected string to have >=20 characters",
        "datasets_or_cohorts.3.description: Too small: expected string to have >=20 characters"
      ],
      "content": "{\n    \"paper\": {\n        \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n        \"doi\": \"10.1038/s41586-025-09006-8\",\n        \"publication_year\": 2025,\n        \"domain\": \"oncology-immunology\",\n        \"study_type\": \"preclinical+retrospective\"\n    },\n    \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n    \"datasets_or_cohorts\": [\n        {\n            \"id\": \"mouse-efficacy-cohort\",\n            \"label\": \"Mouse efficacy cohort (combination therapy)\",\n            \"sample_size_or_observations\": \"78\",\n            \"description\": \"78 tumor-bearing mice pooled across repeat experiments.\"\n        },\n        {\n            \"id\": \"mouse-control-cohort\",\n            \"label\": \"Mouse control cohort (vaccine only, ICI only, and vehicle)\",\n            \"sample_size_or_observations\": \"84\",\n            \"description\": \"84 tumor-bearing mice pooled across matched controls.\"\n        },\n        {\n            \"id\": \"human-retrospective-cohort\",\n            \"label\": \"Human retrospective metastatic cohort\",\n            \"sample_size_or_observations\": \"130\",\n            \"description\": \"130 patients total.\"\n        },\n        {\n            \"id\": \"human-vaccinated-subgroup\",\n            \"label\": \"Human vaccinated subgroup\",\n            \"sample_size_or_observations\": \"43\",\n            \"description\": \"43 patients.\"\n        }\n    ],\n    \"major_limitations\": [\n        \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n        \"Vaccination timing relative to ICI initiation varied across patients.\",\n        \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n        \"Mouse model effects may not map one-to-one to all human tumors.\"\n    ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n    \"findings\": [\n        {\n            \"id\": \"Q01\",\n            \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n            \"value\": \"62.3%\",\n            \"comparator_or_baseline\": \"37.3%\",\n            \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n            \"evidence_line_refs\": [\"L28\"]\n        },\n        {\n            \"id\": \"Q02\",\n            \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n            \"value\": \"40.6%\",\n            \"comparator_or_baseline\": \"20.6%\",\n            \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n            \"evidence_line_refs\": [\"L29\"]\n        },\n        {\n            \"id\": \"Q03\",\n            \"metric\": \"Retrospective human survival comparison p-value\",\n            \"value\": \"p=0.01\",\n            \"comparator_or_baseline\": \"N/A\",\n            \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n            \"evidence_line_refs\": [\"L30\"]\n        },\n        {\n            \"id\": \"Q04\",\n            \"metric\": \"Type I interferon response score (normalized units)\",\n            \"value\": \"3.1\",\n            \"comparator_or_baseline\": \"1.0\",\n            \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n            \"evidence_line_refs\": [\"L31\"]\n        },\n        {\n            \"id\": \"Q05\",\n            \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n            \"value\": \"2.4x\",\n            \"comparator_or_baseline\": \"1.0x\",\n            \"interpretation\": \"Checkpoint axis became more targetable\",\n            \"evidence_line_refs\": [\"L32\"]\n        }\n    ],\n    \"controls_or_null_results\": [\n        {\n            \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n            \"evidence_line_ref\": \"L36\"\n        },\n        {\n            \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n            \"evidence_line_ref\": \"L37\"\n        },\n        {\n            \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n            \"evidence_line_ref\": \"L38\"\n        },\n        {\n            \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n            \"evidence_line_ref\": \"L39\"\n        }\n    ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n    \"claims\": [\n        {\n            \"claim_id\": \"C01\",\n            \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0\",\n                    \"line_ref\": \"L31\"\n                },\n                {\n                    \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n                    \"line_ref\": \"L39\"\n                }\n            ],\n            \"caveat\": \"The reported effects are based on preclinical models and retrospective human data, not from a prospective randomized trial.\"\n        },\n        {\n            \"claim_id\": \"C02\",\n            \"claim\": \"Interferon-associated antigen processing and presentation pathways increase after vaccination.\",\n            \"strength\": \"strong\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%\",\n                    \"line_ref\": \"L28\"\n                },\n                {\n                    \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\",\n                    \"line_ref\": \"L29\"\n                }\n            ],\n            \"caveat\": \"The measurements of antigen presentation were from mouse models and may not fully represent human tumor biology.\"\n        },\n        {\n            \"claim_id\": \"C03\",\n            \"claim\": \"The mRNA vaccination improves tumor visibility to T cells and increases immune infiltration.\",\n            \"strength\": \"moderate\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x\",\n                    \"line_ref\": \"L33\"\n                },\n                {\n                    \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n                    \"line_ref\": \"L44\"\n                }\n            ],\n            \"caveat\": \"The observed increase in T-cell density is a valuable indicator, but does not solely prove a direct causal link to improved tumor destruction in humans.\"\n        },\n        {\n            \"claim_id\": \"C04\",\n            \"claim\": \"Prior mRNA vaccination is associated with improved survival in patients receiving ICI treatment.\",\n            \"strength\": \"tentative\",\n            \"evidence\": [\n                {\n                    \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A\",\n                    \"line_ref\": \"L30\"\n                },\n                {\n                    \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n                    \"line_ref\": \"L30\"\n                }\n            ],\n            \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n        }\n    ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n    \"headline\": \"Could mRNA vaccines help treat cancer? A new study suggests they can make tumors more responsive to immunotherapy.\",\n    \"plain_language_summary\": \"Immunotherapy is a promising cancer treatment, but it doesn't work for everyone. Many tumors can hide from the immune system. This study explored a new strategy: injecting mRNA vaccines directly into tumors in mice. The vaccines triggered a strong immune response inside the tumors, making them more visible to the immune system. When combined with an existing immunotherapy drug, this approach led to better tumor control. The researchers also looked at data from human cancer patients who had received COVID-19 mRNA vaccines. They found that vaccinated patients who later received immunotherapy tended to have better survival. While these findings are exciting, the human data is from a look-back study, not a controlled trial. More research is needed to confirm if this strategy will be a safe and effective new way to treat cancer in people.\",\n    \"what_is_new\": [\n        \"Injecting mRNA vaccines into tumors makes them more sensitive to immunotherapy in mice.\",\n        \"The vaccine triggers a type I interferon response, which helps the immune system 'see' the tumor.\",\n        \"A retrospective study in humans suggests a link between COVID-19 vaccination and better outcomes for patients on immunotherapy.\"\n    ],\n    \"why_caution_is_needed\": [\n        \"The main findings are from mouse studies, which don't always translate to humans.\",\n        \"The human data is retrospective, meaning it wasn't from a controlled clinical trial, so other factors could explain the results.\",\n        \"The timing and type of mRNA vaccine might matter, and this study couldn't control for that.\",\n        \"More research, especially prospective, randomized clinical trials, is needed to confirm these findings.\"\n    ],\n    \"glossary\": [\n        {\n            \"term\": \"Immune Checkpoint Inhibitors (ICIs)\",\n            \"definition\": \"A type of cancer immunotherapy that blocks proteins that stop the immune system from attacking cancer cells.\"\n        },\n        {\n            \"term\": \"mRNA Vaccine\",\n            \"definition\": \"A vaccine that uses a piece of genetic material (mRNA) to teach the body how to make a protein that triggers an immune response.\"\n        },\n        {\n            \"term\": \"Intratumoral\",\n            \"definition\": \"Directly into a tumor.\"\n        },\n        {\n            \"term\": \"Type I Interferon\",\n            \"definition\": \"A group of proteins that play a key role in the body's immune response to viruses and can also help fight cancer.\"\n        }\n    ],\n    \"open_questions\": [\n        \"Would this approach work in a large, prospective, randomized human trial?\",\n        \"What is the best timing for mRNA vaccination in relation to immunotherapy?\",\n        \"Does this effect apply to all types of cancer?\"\n    ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": ["list_directory", "read_file", "write_file"],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-12T13:25:39.437Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-12T13:25:54.272Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-12T13:26:08.709Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-12T13:26:12.078Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-12T13:26:21.071Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-12T13:26:28.539Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-12T13:26:48.401Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-12T13:27:14.374Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-12T13:29:21.798Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-12T13:29:54.370Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-12T13:30:09.695Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 5,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [
        "output/study_overview.json is schema-invalid and flagged as grounding-invalid (schemaValid: false; groundingValid: false). This fails the requirement that outputs be coherent and useful for downstream review, because a key overview artifact cannot be reliably consumed.",
        "output/study_overview.json incompletely represents the reported cohorts: it lists the vaccinated subgroup (43) but omits the unvaccinated subgroup (87) explicitly reported in the source (L23). This is a material cohort element for the retrospective comparison design (L15, L21–L23).",
        "Line-referencing requirement is not met consistently: quantitative_findings.json and claim_audit.json include line refs, but study_overview.json and public_summary.json provide no line references at all. The rubric explicitly requires that 'Line references are valid and map to the numbered report lines below'—missing refs reduces auditability.",
        "Coverage gap in quantitative_findings.json: it omits a key quantitative endpoint reported in the table—intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x (L33). This is a main mechanistic/phenotypic quantitative finding and its absence weakens completeness.",
        "The overview cohort descriptions are very short (and were caught by validation), which practically reduces usefulness for review/triage even if the numbers are correct (e.g., '43 patients.'), and contributes to the schema failure noted above."
      ],
      "summary": "Most numeric values that are included (immunopeptidome fractions, MHC-I peptidome fractions, p-value, IFN score, PD-L1 fold-change) are faithful to the report with valid line references (L28–L32), and key controls/null results are correctly grounded (L36–L39). However, the package fails overall because the study overview JSON is not schema/grounding valid and omits the unvaccinated subgroup (L23), line references are missing in two deliverables, and one core quantitative finding (CD8 density, L3"
    }
  }
}
